Clinical Trial Detail

NCT ID NCT03164616
Title Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors AstraZeneca
Indications

lung non-small cell carcinoma

Therapies

Durvalumab + Tremelimumab

Cisplatin + Pemetrexed Disodium

Carboplatin + Pemetrexed Disodium

Cisplatin + Gemcitabine

Carboplatin + Gemcitabine

Durvalumab

Carboplatin + Nab-paclitaxel

Age Groups: adult senior

Additional content available in CKB BOOST